AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3918356 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg nebulised sodium cromoglycate
Number of subjects: 11
Study 3918356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30516064 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus on Exercise Reporting Template
Number of subjects: 0
Study 30516064 — intervention group
Group type: EXPERIMENTAL
Intervention: Template for Intervention Description and Replication
Number of subjects: 0
Study 30516064 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus on Therapeutic Exercise Training
Number of subjects: 0
Study 30516064 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 American College of Sports Medicine guidelines (aerobic)
Number of subjects: 0
Study 30516064 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 American College of Sports Medicine guidelines (flexibility and resistance)
Number of subjects: 0
Study 30516064 — intervention group
Group type: COMPARATOR
Intervention: All reporting tools
Number of subjects: 0
Study 30012190 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) of all brain metastases (up to ten lesions)
Number of subjects: 56
Study 30012190 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 56
Study 30012190 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 56
Study 26620682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 76
Study 26620682 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 76
Study 26620682 — intervention group
Group type: COMPARATOR
Intervention: Topical pharyngeal anaesthesia
Number of subjects: 76
Study 25027170 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA-CHA (split-course accelerated hyperfractionated irradiation)
Number of subjects: 101
Study 25027170 — intervention group
Group type: COMPARATOR
Intervention: Conventional (Conv.) arm
Number of subjects: 101
Study 22789440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1g intravenously in a single dose before surgery)
Number of subjects: 320
Study 22789440 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1g intravenously in a single dose before surgery)
Number of subjects: 320
Study 20508026 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(B) adjuvanted split virion vaccine
Number of subjects: 943
Study 20508026 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted whole virion vaccine
Number of subjects: 943
Study 18593681 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administered via pen devices (n = 49)
Number of subjects: 94
Study 18593681 — intervention group
Group type: COMPARATOR
Intervention: Conventional vials and syringes (n = 45)
Number of subjects: 94
Study 15973830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic periodontal treatment (Group 1)
Number of subjects: 50
Study 15973830 — intervention group
Group type: COMPARATOR
Intervention: No ultrasonic scaling (Group 2)
Number of subjects: 50
Study 15973830 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3) - adults without PD, Community Periodontal Index of Treatment Needs = 0
Number of subjects: 50
Study 12048127 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 5 mg/day
Number of subjects: 100
Study 12048127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg/day
Number of subjects: 100
Study 12048127 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 5 mg/day plus vitamin C 500 mg/day
Number of subjects: 100
Study 12048127 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 100
Study 10453490 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH) 0.15 IU/(kg.day)
Number of subjects: 18
Study 10453490 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 10453490 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH)
Number of subjects: 18
Study 8190404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloroplasty or pyloromyotomy (group A)
Number of subjects: 38
Study 8190404 — intervention group
Group type: COMPARATOR
Intervention: No drainage procedures (group B)
Number of subjects: 38
Study 8190404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups A and B combined
Number of subjects: 38
Study 2455109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg b.i.d. in a slow-release formulation)
Number of subjects: 17
Study 2455109 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 17
Study 2455109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Atenolol combination
Number of subjects: 17
Study 2455109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31853609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin 3500 IU q24h starting 6 hours after procedure for at least 10 days
Number of subjects: 78
Study 31853609 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 IU q24h starting 6 hours after procedure for at least 10 days
Number of subjects: 78
Study 29476776 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (nonspecific β1‐, β2‐adrenergic receptor inverse agonist)
Number of subjects: 0
Study 29476776 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 29476776 — intervention group
Group type: COMPARATOR
Intervention: Catecholamine stimulation
Number of subjects: 0
Study 29476776 — intervention group
Group type: COMPARATOR
Intervention: Basal β2‐AR ubiquitination
Number of subjects: 0
Study 27720505 — intervention group
Group type: EXPERIMENTAL
Intervention: S-AM/TEL 2.5/40 mg
Number of subjects: 183
Study 27720505 — intervention group
Group type: EXPERIMENTAL
Intervention: S-AM/TEL 5/40 mg
Number of subjects: 183
Study 27720505 — intervention group
Group type: COMPARATOR
Intervention: TEL 80 mg
Number of subjects: 183
Study 27720505 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 183
Study 24667161 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1371
Study 24667161 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 1371
Study 22532005 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective valence during a 10-min treadmill walk
Number of subjects: 146
Study 22532005 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective valence during a 2-min cool down
Number of subjects: 146
Study 22532005 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective valence during a postcool-down seated rest
Number of subjects: 146
Study 20820459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoom 2 bleaching agent applied to labial surfaces
Number of subjects: 20
Study 20820459 — intervention group
Group type: COMPARATOR
Intervention: No bleaching treatment (Control)
Number of subjects: 20
Study 20820459 — intervention group
Group type: EXPERIMENTAL
Intervention: Polishing treatment for both groups
Number of subjects: 20
Study 18005078 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (twice weekly for 12 weeks)
Number of subjects: 28
Study 18005078 — intervention group
Group type: COMPARATOR
Intervention: Control (normal treatment including encouragement to walk regularly)
Number of subjects: 28
Study 16633088 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (IND) 2.5 mg od
Number of subjects: 25
Study 16633088 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide (BDZ) 2.5 mg od
Number of subjects: 25
Study 14633756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil TCI (0.25 ng x ml(‐1) effect‐site concentration at extubation)
Number of subjects: 30
Study 14633756 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil TCI with morphine bolus (0.15 mg x kg(‐1))
Number of subjects: 30
Study 14633756 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil TCI
Number of subjects: 30
Study 14633756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil TCI
Number of subjects: 30
Study 11304887 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention level defined in digit span test
Number of subjects: 40
Study 8827850 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg estradiol added to neuroleptic treatment for eight weeks
Number of subjects: 11
Study 8827850 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic treatment alone
Number of subjects: 11
Study 7967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine, 500 mg/day
Number of subjects: 80
Study 7967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 320 mg/day
Number of subjects: 80
Study 7967338 — intervention group
Group type: COMPARATOR
Intervention: No disaggregants (Control Group 3)
Number of subjects: 80
Study 3519095 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hexetidine
Number of subjects: 10
Study 3519095 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 30222637 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous microneedle RF treatment (67°C/4‐second duration)
Number of subjects: 50
Study 27977720 — intervention group
Group type: EXPERIMENTAL
Intervention: RBANS neurocognitive test battery administered on admission and again at discharge (mean time 4.1 weeks, SD 1.86 weeks)
Number of subjects: 84
Study 27977720 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PANSS negative symptoms
Number of subjects: 84
Study 27977720 — intervention group
Group type: COMPARATOR
Intervention: Comparison between subjects with schizophrenia and those with other psychotic disorders
Number of subjects: 84
Study 25509967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rajyoga meditation in addition to routine medical treatment (analgesics and muscle relaxants)
Number of subjects: 50
Study 25509967 — intervention group
Group type: COMPARATOR
Intervention: Control group (analgesics and muscle relaxants only)
Number of subjects: 50
Study 22070769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 22070769 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 0
Study 22070769 — intervention group
Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 0
Study 20159703 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 implantation
Number of subjects: 68
Study 20159703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodine-125 implantation)
Number of subjects: 68
Study 17706461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplayer group (participated in a weekly IDSVG multiplayer class)
Number of subjects: 27
Study 17706461 — intervention group
Group type: COMPARATOR
Intervention: Home group (instructed to play IDSVG at home)
Number of subjects: 27
Study 17706461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplayer group
Number of subjects: 27
Study 17706461 — intervention group
Group type: COMPARATOR
Intervention: Home group
Number of subjects: 27
Study 16209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low left ventricular ejection fraction (< 30%) at 1 year
Number of subjects: 291
Study 16209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of right ventricular dysfunction
Number of subjects: 291
Study 16209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular dysfunction
Number of subjects: 291
Study 12427648 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-high-density lipoprotein cholesterol (non-HDL-C)
Number of subjects: 1514
Study 12427648 — intervention group
Group type: COMPARATOR
Intervention: HDL-C and LDL-C
Number of subjects: 1514
Study 10361649 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus relaxation therapy (relaxation group; n = 76)
Number of subjects: 156
Study 10361649 — intervention group
Group type: COMPARATOR
Intervention: Exercise training only (control group; n = 80)
Number of subjects: 156
Study 10361649 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 156
Study 7741790 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide‐HCl (Cerucal)
Number of subjects: 12
Study 2048369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 44
Study 2048369 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 44
Study 2048369 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 44
Study 2048369 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 44
Study 155507 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide-neomycin-amphotericin (HNA) cream
Number of subjects: 80
Study 155507 — intervention group
Group type: COMPARATOR
Intervention: Iodochlorhydroxyquin-hydrocortisone (I-HC)
Number of subjects: 80
Study 155507 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC)
Number of subjects: 80
Study 30684710 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 120
Study 30684710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% mannitol plus 10% glycerol
Number of subjects: 120
Study 30684710 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 120
Study 29136453 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional interferon beta (3 million units once per day for 10 consecutive days every 8 weeks for a total of 3 courses, then 1-day injection every 4 weeks for 2.5 years)
Number of subjects: 240
Study 29136453 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional interferon beta
Number of subjects: 240
Study 29136453 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 240
Study 26334108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified maintenance (in-person visits plus telephone calls)
Number of subjects: 106
Study 26334108 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance (mailed materials)
Number of subjects: 106
Study 23182126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 1978
Study 23182126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100mg
Number of subjects: 1978
Study 23182126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1978
Study 23182126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4mg
Number of subjects: 1978
Study 21929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Single talker auditory training
Number of subjects: 69
Study 21929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple talker auditory training
Number of subjects: 69
Study 18182756 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 27
Study 16644310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified medical therapy
Number of subjects: 824
Study 16644310 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 824
Study 14663807 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning splint and plates
Number of subjects: 23
Study 10964145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10%
Number of subjects: 70
Study 10964145 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 70
Study 8695135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotline fluid warmer
Number of subjects: 49
Study 8695135 — intervention group
Group type: COMPARATOR
Intervention: Flotem IIe fluid warmer
Number of subjects: 49
Study 1511646 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (10 mg)
Number of subjects: 12
Study 1511646 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide (10 mg)
Number of subjects: 12
Study 1511646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6511100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (100ppm toluene + ethanol)
Number of subjects: 4
Study 6511100 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (100ppm toluene + cimetidine)
Number of subjects: 4
Study 6511100 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (100ppm toluene + propranolol)
Number of subjects: 4
Study 6511100 — intervention group
Group type: COMPARATOR
Intervention: Control (100ppm toluene)
Number of subjects: 4
Study 6511100 — intervention group
Group type: COMPARATOR
Intervention: Control (200ppm toluene)
Number of subjects: 4
Study 29387318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 88
Study 29387318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27031480 — intervention group
Group type: EXPERIMENTAL
Intervention: PWD living alone
Number of subjects: 511
Study 27031480 — intervention group
Group type: COMPARATOR
Intervention: PWD not living alone
Number of subjects: 511
Study 25662857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 40
Study 25662857 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 23308361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceuticals containing soy isoflavones (60 mg) and berberine (500 mg)
Number of subjects: 40
Study 23308361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21127274 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin dynamics test (TDT)
Number of subjects: 220
Study 21127274 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 220
Study 21127274 — intervention group
Group type: COMPARATOR
Intervention: Aortic valve replacement (AVR) with warfarin treatment
Number of subjects: 220
Study 21127274 — intervention group
Group type: EXPERIMENTAL
Intervention: F(1+2) levels
Number of subjects: 220
Study 19149269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferulate intravenous drip after 24 hours
Number of subjects: 60
Study 19149269 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (dehydrating, cytidine diphosphocholine, controlling blood pressure, blood sugar and complicating diseases)
Number of subjects: 60
Study 16534180 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg b.i.d. via Foradil Aerolizer)
Number of subjects: 38
Study 16534180 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (18 microg o.d. via Spiriva HandiHaler)
Number of subjects: 38
Study 16534180 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 38
Study 16534180 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 38
Study 12680747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 26
Study 12680747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12680747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (adequate treatment)
Number of subjects: 26
Study 12680747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adequate treatment)
Number of subjects: 26
Study 10890988 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (methylprednisolone or prednisolone at 1 mg/kg, increased by 50% every 5 to 10 days)
Number of subjects: 33
Study 10890988 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus cyclosporine (5 mg/kg)
Number of subjects: 33
Study 8822971 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg SDZ‐WAG 994
Number of subjects: 50
Study 8822971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg SDZ‐WAG 994
Number of subjects: 50
Study 8822971 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg SDZ‐WAG 994
Number of subjects: 50
Study 8822971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1454457 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 18
Study 1454457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3913459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg 4 times daily) for up to 12 weeks
Number of subjects: 11
Study 3913459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3913459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 11
Study 3913459 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir and Placebo
Number of subjects: 11
Study 3913459 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Oral acyclovir
Number of subjects: 11
Study 30474929 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA) patients
Number of subjects: 60
Study 30474929 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 30474929 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA patients with higher vigorous physical activity
Number of subjects: 60
Study 30474929 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA patients
Number of subjects: 60
Study 28549799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led patient-centered pharmaceutical care (PC)
Number of subjects: 514
Study 28549799 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 514
Study 27575314 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora education, Video education, Combined promotora and video education
Number of subjects: 784
Study 27575314 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 784
Study 23676632 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) acupuncture (AP)
Number of subjects: 40
Study 23676632 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine (verum CHM)
Number of subjects: 40
Study 23676632 — intervention group
Group type: COMPARATOR
Intervention: Placebo CHM
Number of subjects: 40
Study 20152665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) during orthodontic treatment in group 1 (25 patients)
Number of subjects: 48
Study 20152665 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances without RME in group 2 (23 patients)
Number of subjects: 48
Study 18836152 — intervention group
Group type: COMPARATOR
Intervention: Diagnosed diabetes (self-reported diabetes or diabetic medication use; n = 163)
Number of subjects: 1917